Degludec is an ultralong-acting, once-daily basal insulin that is approved for use in adults, adolescents, and children with diabetes. Previous open-label studies have shown lower day-to-day variability in the glucose-lowering effect and lower rates of hypoglycemia among patients who received degludec than among those who received basal insulin glargine. However, data are lacking on the cardiovascular safety of degludec.

Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes

Baldassarre, Maria Pompea Antonia;
2017-01-01

Abstract

Degludec is an ultralong-acting, once-daily basal insulin that is approved for use in adults, adolescents, and children with diabetes. Previous open-label studies have shown lower day-to-day variability in the glucose-lowering effect and lower rates of hypoglycemia among patients who received degludec than among those who received basal insulin glargine. However, data are lacking on the cardiovascular safety of degludec.
File in questo prodotto:
File Dimensione Formato  
nejmoa1615692.pdf

accesso aperto

Tipologia: PDF editoriale
Dimensione 316.53 kB
Formato Adobe PDF
316.53 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11564/794731
Citazioni
  • ???jsp.display-item.citation.pmc??? 182
  • Scopus 468
  • ???jsp.display-item.citation.isi??? 387
social impact